ClinicalTrials.gg

Program

HM17321

A development code.

Its studies are mostly in Obesity, led by Hanmi Pharmaceutical.

Furthest: phase 1, since Oct 16, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical11 open or runningphase 1since Oct 16, 2025Oct 16, 2025Mar 2027phase 1 · NCT07219589
  • Named in hoffmann la roche’s own pipeline as RG7985 UCN-2 analog (Hanmi), phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2025First study: phase 1 study in ObesityFirst studyNCT07219589 · 90 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 1 study in ObesityNCT07219589

TargetBeta

UCN2 →read by rule
“This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321, a urocortine 2 (UCN2) analog, administered by subcutaneous (SC) injection in healthy and obes…”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07219589Obesity · United States1RecruitingMar 202790

How it is read

Names in the registry

  • “HM17321”, 1 entry

Codes read as this program: HM17321.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.